Zacks Research Raises Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Research analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for AngioDynamics in a report issued on Thursday, March 6th. Zacks Research analyst D. Dey now anticipates that the medical instruments supplier will post earnings of ($0.10) per share for the quarter, up from their prior forecast of ($0.11). The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics' Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at ($0.17) EPS.

Separately, HC Wainwright lifted their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, January 10th.

AngioDynamics Price Performance

Shares of ANGO stock traded up $0.37 during trading on Monday, reaching $8.74. The company had a trading volume of 267,887 shares, compared to its average volume of 741,474. The company has a market capitalization of $353.67 million, a PE ratio of -1.55 and a beta of 0.56. The firm's 50 day simple moving average is $10.82 and its two-hundred day simple moving average is $8.59. AngioDynamics has a one year low of $5.26 and a one year high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm had revenue of $72.90 million during the quarter, compared to analysts' expectations of $70.93 million. During the same period in the prior year, the company posted ($0.05) earnings per share. AngioDynamics's revenue for the quarter was down .1% on a year-over-year basis.

Remove Ads

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares of the company's stock, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.40% of the company's stock.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of AngioDynamics by 4.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,968 shares of the medical instruments supplier's stock worth $201,000 after buying an additional 969 shares during the period. Rhumbline Advisers boosted its stake in shares of AngioDynamics by 1.7% in the 4th quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier's stock valued at $554,000 after purchasing an additional 1,021 shares in the last quarter. Invesco Ltd. boosted its stake in shares of AngioDynamics by 1.2% in the 4th quarter. Invesco Ltd. now owns 119,249 shares of the medical instruments supplier's stock valued at $1,092,000 after purchasing an additional 1,451 shares in the last quarter. OneDigital Investment Advisors LLC grew its holdings in shares of AngioDynamics by 14.0% in the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock worth $111,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of AngioDynamics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier's stock worth $3,014,000 after purchasing an additional 2,270 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.